Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivastigmine and memantine for cognitive problems after electroconvulsive therapy
IRCT20190119042417N2Phase 3Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Jun 2022
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of rivastigmine and memantine in confusion and electroconvulsive therapy-associated cognitive impairment (ECT-ICI), sponsored by Shahid Beheshti University of Medical Sciences. Started Jun 2022; status: completed.
02
Drugs
rivastigminememantine
03
Conditions
confusionelectroconvulsive therapy-associated cognitive impairment (ECT-ICI)
Beyond the preview
Go deeper on IRCT20190119042417N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20190119042417N2.